Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches.

Vivek Asati, Arjun Anant, Preeti Patel, Kamalpreet Kaur, G D Gupta

Journal: European journal of medicinal chemistry 2022;225():113781

PMID: 34438126

Abstract

["Pyrazolopyrimidine scaffold is one of the privileged heterocycles in drug discovery. This scaffold produced numerous biological activities in which anticancer is important one. Previous studies showed its importance in interactions with various receptors such as growth factor receptor, TGFBR2 gene, CDK2\/cyclin E and Abl kinase, adenosine receptor, calcium-dependent Protein Kinase, Pim-1 kinase, Potent Janus kinase 2, BTK kinase, P21-activated kinase 1, extracellular signal-regulated kinase 2, histone lysine demethylase and Human Kinesin-5. However, there is a need of numerous studies for the discovery of target based potential compounds. The structure activity relationship studies may help to explore the generation of potential compounds in short time period. Therefore, in the present review we tried to explore the structural aspects of Pyrazolopyrimidine with their structure activity relationship against various targets for the development of potential compounds. The current review is the compilation of significant advances made on Pyrazolopyrimidines reported between 2015 and 2020.",{"copyright":"Copyright \u00a9 2021. Published by Elsevier Masson SAS."}]
Address: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Electronic address: [email protected].; Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India.; Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.